Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. News
  7. Summary
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
62.21 USD   -0.99%
06:02aKite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating

05/13/2022 | 12:55pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
06:02aKite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Tr..
BU
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
MT
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
BU
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
CI
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
AQ
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
BU
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
MT
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
AQ
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
BU
06/24Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opin..
CI
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 543 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 327 M - -
P/E ratio 2022 17,8x
Yield 2022 4,62%
Capitalization 78 809 M 78 809 M -
EV / Sales 2022 3,88x
EV / Sales 2023 3,80x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 62,83 $
Average target price 69,65 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.86%44 742
BIONTECH SE-48.01%32 574
GENMAB A/S-13.61%20 738